CD44 and cancer: Despite these discouraging examples, a clinical trial testing a Notch signaling pathway inhibitor in BCSCs successfully reduced ALDH+ cells, along with other cancer stem cell markers such as CD44/CD24 and mammosphere-forming efficiency [53].